An update on the use of 5alpha-reductase inhibitors.

Abstract

Twelve years ago, finasteride, the first 5alpha-reductase inhibitor, was introduced as drug therapy for benign prostatic hyperplasia, and more recently dutasteride has emerged as an alternative. The efficacy, safety and ability of these 5alpha-reductase inhibitors to reverse the natural progression of benign prostatic hyperplasia have been convincingly demonstrated and both drugs are now well established in the medical armamentarium against the disease. Given the multifactorial etiology of benign hyperplasia, the usefulness of 5alpha-reductase inhibitors in combination with alpha adrenergic blockers has also been investigated and justified in select patients. Wider applications of 5alpha-reductase inhibitors are also emerging, though their perhaps most important new role as chemopreventive agents remains unclear.

• Authors: Charlotte L Foley, Simon R J Bott, Iqbal S Shergill, Roger S Kirby
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 40 Issue 3 Pg. 213-23 (Mar 2004) ISSN: 1699-3993 [Print] Spain
• PMID: 15148530 (Publication Type: Journal Article, Review)
• Copyright: c) 2004 Prous Science. All rights reserved

Chemical References

• Adrenergic alpha-Antagonists
• Azasteroids
• Isoenzymes
• Finasteride
• Cholestenone 5 alpha-Reductase
• Dutasteride

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Azasteroids (administration & dosage, therapeutic use)
• Cholestenone 5 alpha-Reductase (antagonists & inhibitors)
• Drug Therapy, Combination
• Dutasteride
• Finasteride (administration & dosage, therapeutic use)
• Humans
• Isoenzymes (antagonists & inhibitors)
• Male
• Prostatic Hyperplasia (drug therapy)
• Prostatic Neoplasms (prevention & control)
• Randomized Controlled Trials as Topic